|
|
|
|
|
by vczf
314 days ago
|
|
From the abstract of the paper: > Replacement therapy with lithium orotate, which is a Li salt with reduced amyloid binding, prevents pathological changes and memory loss in AD mouse models and ageing wild-type mice.
https://www.nature.com/articles/s41586-025-09335-xAnother source on lithium orotate: > LiOr is proposed to cross the blood–brain barrier and enter cells more readily than Li2CO3, which will theoretically allow for reduced dosage requirements and ameliorated toxicity concerns.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8413749/ |
|
If cells in the brain are being deprived of lithium due to sequestration by amyloid beta plaques, then a bioavailable form of lithium that is resistant to sequestration may treat the pathology.